Pacira BioSciences Returns to Profitability in 2025 with Strong Revenue Growth and Strategic Progress
PCRX is trading near its 52-week low of $18.8 (13% above the low) on elevated volume (2.4× avg).
Summary
Pacira BioSciences, Inc. achieved GAAP net income of $7.0 million in 2025, reversing a prior-year loss, driven by revenue growth and improved gross margins. The company advanced its strategic goals with new partnerships, product expansions, and a significant share repurchase program, alongside favorable legal outcomes.
Key Events · Earnings and Guidance · PCRX
-
Return to GAAP Net Income
Reported GAAP net income of $7.0 million for 2025, a significant turnaround from a $99.6 million net loss in 2024.
-
Revenue Growth and Margin Expansion
Total revenues increased 4% to $726.4 million in 2025, with EXPAREL sales up 5% and iovera® up 6%. Gross margin improved by 3 percentage points to 79%.
-
Strategic Partnerships and Pipeline Advancement
Entered a co-promotion agreement with Johnson & Johnson MedTech for ZILRETTA, licensed PCRX-2002 from AmacaThera, and partnered with LG Chem for EXPAREL in Asian-Pacific markets. FDA cleared a new iovera® Smart Tip for chronic low back pain.
-
Significant Share Repurchase Program
Repurchased $151.4 million of common stock in 2025 under a $300 million authorization, with $150 million remaining for future repurchases.
Analysis · PCRX · Life Sciences
Pacira BioSciences, Inc. reported a significant financial turnaround in 2025, achieving GAAP net income of $7.0 million, a notable improvement from a $99.6 million net loss in 2024. This performance was supported by a 4% increase in total revenues to $726.4 million and a 3 percentage point expansion in gross margin to 79%. The company also made substantial progress on its strategic 5x30 plan, including expanding its product portfolio through new partnerships and product clearances. Key legal victories, such as the $28.3 million repayment from the RDF royalty dispute and the dismissal of a securities class action, further bolstered financial results. However, the company incurred a $25.9 million impairment charge related to its ZILRETTA shoulder asset and faces ongoing patent litigation for EXPAREL, indicating continued investment and legal defense efforts.
At the time of this filing, PCRX was trading at $21.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $971.9M. The 52-week trading range was $18.80 to $27.64. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.